WORLD JOURNAL OF PHARMACEUTICAL RESEARCH
Coden USA: WJPRAP Impact Factor 8.63
Volume 15, Issue 16, 407-415. Review Article ISSN 2277–7105

PHARMACODYNAMIC ACTION OF VIRECHANA KARMA IN MADHUMEHA (TYPE 2 DIABETES MELLITUS

[1]Dr. Umesh Shukla, [2]*Dr. Sunita Rajput, [3]Dr. Kamini Soni, [4]Dr. Deepika Thakur, [5]Dr. Minakshee Chouhan

[1]Professor and HOD Department of Panchkarma, Pt. Khushilal Sharma Govt. Ayurveda College and Institute, Bhopal.
[2]Lecturer, Department of Agad Tantra, Pt. Khushilal Sharma Govt. Ayurveda College and Institute, Bhopal.
[3]Professor (I/C), Department of Panchkarma, Pt. Khushilal Sharma Govt. Ayurveda College and Institute, Bhopal.
[4]Lecturer, Department of Dravyaguna, Pt. Khushilal Sharma Govt. Ayurveda College and Institute, Bhopal.
[5]MD Scholar, Dept. of Panchkarma, Pt. Khushilal Sharma Govt. Ayurveda College and Institute, Bhopal, M.P.

Article Received on 15 July 2026,
Article Revised on 05 August 2026,
Article Published on 16 August 2026,

https://doi.org/10.5281/zenodo.21914204

***Corresponding Author**

Dr. Sunita Rajput

Lecturer, Department of Agad Tantra, Pt. Khushilal Sharma Govt. Ayurveda College and Institute, Bhopal.

How to cite this Article: [1]Dr. Umesh Shukla, [2]*Dr. Sunita Rajput, [3]Dr. Kamini Soni, [4]Dr. Deepika Thakur, [5]Dr. Minakshee Chouhan. (2026). Pharmacodynamic Action of Virechana Karma In Madhumeha (Type 2 Diabetes Mellitus. World Journal of Pharmaceutical Research, 15(16), 407–415.

ABSTRACT

Background: Madhumeha, described under the spectrum of Prameha in classical Ayurvedic literature, closely resembles Type 2 Diabetes Mellitus (T2DM), a chronic metabolic disorder characterized by insulin resistance, β-cell dysfunction, chronic low-grade inflammation, oxidative stress, and metabolic endotoxemia.[1,3] Ayurveda attributes its pathogenesis to Kapha-Pitta aggravation, Medo-dhatu vriddhi, Agnimandya, and Srotorodha.[4,7] **Objective:** To explore the pharmacodynamic basis of Virechana Karma in Madhumeha through classical Ayurvedic principles and contemporary molecular mechanisms. **Materials and Methods:** Classical Ayurvedic texts including Charaka Samhita, Sushruta Samhita, and Ashtanga Hridaya were critically reviewed. Contemporary biomedical literature addressing insulin resistance, inflammatory signaling, oxidative stress, gut microbiota, bile acid signaling, hepatometabolic regulation, and neuroendocrine stress pathways was analyzed. Conceptual correlations were constructed using a systems biology framework. **Results:** Virechana Karma, the principal Pittahara Shodhana therapy, may modulate

inflammatory cytokines (TNF-α, IL-6, IL-1β), improve insulin signaling (IRS-1/PI3K/Akt pathway), reduce oxidative stress, alter gut microbial composition, enhance bile acid receptor activation (FXR/TGR5), and recalibrate neuroendocrine stress responses. These interconnected mechanisms correspond to classical concepts of Agni Deepana, Ama Pachana, Srotoshodhana, and Dosha Shamana. **Conclusion:** Virechana may exert multi-system pharmacodynamic effects relevant to Madhumeha. Rigorous translational research integrating molecular biomarkers and randomized clinical trials is essential for scientific validation and global integration.

KEYWORDS: Virechana, Madhumeha, Prameha, Type 2 Diabetes Mellitus, Panchakarma, Agni, Gut–Liver Axis.

1. INTRODUCTION

Type 2 Diabetes Mellitus represents a growing global health burden driven by sedentary lifestyle, caloric excess, adiposity, and chronic inflammation.[1] The condition is marked by progressive insulin resistance, impaired glucose utilization, dysregulated lipid metabolism, and vascular complications.[2,3]

Ayurveda describes a comparable condition under Prameha, a group of twenty disorders categorized based on doshic predominance.[4] Madhumeha represents the advanced and often irreversible stage characterized by Madhura-mutrata, polyuria, and progressive dhatu kshaya.[5,6] The pathogenesis involves Kapha-Pitta aggravation, Meda dhatu dysfunction, impaired Agni, and accumulation of metabolic toxins (Ama).[6] Charaka describes Prameha as a Santarpanajanya Vyadhi arising from excessive intake of Guru, Snigdha, Madhura Ahara and sedentary habits.[4,7] The samprapti involves:

- Kapha and Meda vriddhi
- Agnimandya
- Kleda accumulation
- Srotorodha
- Ojas dushti

These descriptions parallel visceral adiposity, insulin resistance, metabolic endotoxemia, and chronic inflammation.[8,11]

In Pittanubandha and Meda-dominant states, Shodhana—especially Virechana—is indicated.[6,12] While Panchakarma procedures are traditionally interpreted through Dosha

theory, their systemic physiological impact warrants scientific exploration. This manuscript examines the pharmacodynamic implications of Virechana in Madhumeha from a molecular and systems biology perspective.

2. AYURVEDIC PATHOPHYSIOLOGY OF MADHUMEHA

Nidana (Etiological Factors)

Charaka lists the following causative factors.[4,7]

- Ati-madhura, ati-snigdha, ati-guru ahara
- Divaswapna
- Avyayama
- Alasya
- Beejadosha

These correlate with high-calorie diet, inactivity, obesity, genetic predisposition, and metabolic dysregulation.[1,9]

Samprapti (Pathogenesis)

The pathological sequence includes:[4,6]

1. Kapha-Meda vriddhi
2. Agnimandya
3. Ama formation
4. Srotorodha
5. Vata avarana by Kapha/Meda
6. Ojas dushti

Chronic stage: Dhatu kshaya and Vata predominance (Avarana-janya Madhumeha).

This resembles progression from obesity-induced insulin resistance to β-cell failure and catabolic diabetes.[9,14]

Doshic Involvement

- Kapha: metabolic sluggishness, adiposity
- Pitta: inflammatory and hepatometabolic dysfunction
- Vata: catabolic progression and complications

Srotas Involvement

- Medovaha Srotas
- Mutravaha Srotas

- Rasavaha Srotas
- Raktavaha Srotas

Yakrit (liver) is emphasized in Pittaja disorders, suggesting hepatometabolic significance.

From a biomedical standpoint, these descriptions resemble:
Visceral adiposity, Insulin resistance, Lipotoxicity and Chronic low-grade inflammation.[9,10]
The progressive transformation of Kaphaja Prameha into Madhumeha parallels the transition from metabolic syndrome to overt diabetes.[11]

3. CLASSICAL RATIONALE FOR VIRECHANA IN MADHUMEHA

Virechana is indicated in Pitta-dominant metabolic disorders and diseases involving hepatic and intestinal pathology.[12] It primarily expels vitiated Pitta through the lower gastrointestinal tract. Classical attributes include:[13]

- Pittashodhana
- Raktaprasadana
- Agnideepana
- Srotoshodhana

Therapeutic purgation is traditionally preceded by Snehana (oleation) and Swedana (sudation), enhancing mobilization of vitiated Doshas from peripheral tissues to the gastrointestinal tract.

4. MOLECULAR CORRELATES OF VIRECHANA: SYSTEMS-LEVEL INTERPRETATION

4.1 Modulation of Insulin Resistance

Insulin resistance is associated with impaired insulin receptor signaling via IRS-1 and PI3K/Akt pathways.[14] Chronic inflammation activates serine kinases that inhibit insulin receptor phosphorylation.[15]

By reducing inflammatory burden and metabolic congestion, Virechana may theoretically restore insulin sensitivity through:Reduction of TNF-α and IL-6, Improved adipokine balance, enhanced hepatic insulin signaling.[16]

4.2 Inflammatory Cytokine Regulation

T2DM is characterized by elevated pro-inflammatory mediators including TNF-α, IL-1β, and IL-6.[17] These cytokines interfere with insulin receptor activity and promote β-cell

apoptosis.[18]

Purgative therapies may reduce systemic inflammatory load through:

- Elimination of inflammatory metabolites
- Reduction in endotoxin absorption, Immune recalibration via gut-associated lymphoid tissue.[19]

This aligns with the Ayurvedic concept of Ama pachana and Srotoshodhana.

4.3 Oxidative Stress and Antioxidant Pathways

Persistent hyperglycemia generates reactive oxygen species (ROS)[20] leading to mitochondrial dysfunction. Oxidative stress damages pancreatic β-cells and vascular endothelium.[21]

Certain Virechana dravyas (e.g., Trivrit, Aragvadha) possess antioxidant phytoconstituents such as flavonoids and phenolic compounds.[22,23] These may:

- Enhance endogenous antioxidant enzymes (SOD, catalase)
- Reduce lipid peroxidation
- Protect β-cell integrity

4.4 Gut Microbiota Modulation

Altered gut microbiota contributes to metabolic endotoxemia and insulin resistance.[24] Increased intestinal permeability allows lipopolysaccharide (LPS) translocation, activating TLR-4 mediated inflammation.[25] Microbiota targeted therapies improve glycemic control.[26]

Virechana may

Reduce pathogenic microbial load

Alter microbial diversity

Improve intestinal barrier function

This parallels emerging research on microbiome-targeted metabolic therapy.

4.5 Bile Acid Signaling and Hepatic Metabolism

Bile acids act as signaling molecules through FXR and TGR5 receptors, influencing glucose and lipid metabolism.[27]

Therapeutic purgation increases bile flow and turnover, potentially enhancing FXR-mediated glucose regulation, improving hepatic insulin sensitivity, promoting GLP-1 secretion via

TGR5 activation.[28]

This provides a modern biochemical analogy to Pittashodhana.

4.6 Neuroendocrine Regulation

Stress axis dysregulation elevates cortisol, worsening hyperglycemia.[29] Mind body interventions and detoxification procedures may improve autonomic balance.[30] Panchakarma procedures have been associated with parasympathetic activation and stress reduction.

Neuroendocrine stabilization may indirectly improve glycemic control.

5. CLINICAL EVIDENCE OVERVIEW

Preliminary clinical studies suggest that Virechana:

- Reduces fasting blood glucose
- Lowers postprandial glucose
- Improves lipid profile
- Reduces body weight
- However, rigorous randomized controlled trials with biochemical endpoints remain limited.

6. INTEGRATED MECHANISTIC MODEL

Virechana may exert multi-dimensional effects:

- Ayurvedic Concept
- Biomedical Correlate
- Dosha Shodhana
- Reduction of inflammatory load
- Agni Deepana
- Metabolic enhancement
- Srotoshodhana
- Improved microcirculation
- Ama Pachana
- Detoxification / endotoxin reduction

This integrative framework supports a systems biology interpretation.

DISCUSSION

The integrative interpretation of Virechana suggests multi-axis regulation involving inflammatory, metabolic, microbial, hepatic, and neuroendocrine pathways.

Classical concepts may correspond to modern mechanisms as follows:

Ayurvedic Concept	Possible Molecular Correlate
Agnimandya	Mitochondrial dysfunction, metabolic inflexibility
Ama	Endotoxemia, inflammatory metabolites
Srotorodha	Microvascular dysfunction, lipid accumulation
Meda vriddhi	Visceral adiposity
Pittashodhana	Hepatobiliary modulation, cytokine reduction

Importantly, Virechana may act as a controlled physiological stressor inducing adaptive metabolic recalibration—similar to hormetic responses observed in caloric restriction or intermittent fasting.

However, existing evidence remains largely theoretical or based on small clinical studies.[30]

High-quality randomized controlled trials incorporating:

- HbA1c
- HOMA-IR
- Inflammatory cytokines
- Gut microbiome sequencing
- Bile acid profiling
- Oxidative stress biomarkers are required.

Future research should adopt

- Translational biomarker-driven designs
- Multi-omics approaches
- Standardized Virechana protocols
- Long-term follow-up

Such designs would significantly strengthen evidence for integration into mainstream diabetes management.

7. CONCLUSION

Virechana Karma may influence metabolic regulation through interconnected pathways involving inflammation, oxidative stress, hepatic metabolism, bile acid signaling, and gut microbiota modulation. While classical descriptions frame the therapy within Dosha theory,

emerging biomedical analogies suggest plausible molecular mechanisms. Structured translational research and well-designed clinical trials are required to validate these hypotheses.

ACKNOWLEDGMENT

The authors sincerely acknowledge the invaluable support and cooperation of the **Postgraduate (PG) Scholars, PHI Project Team** Pt. Khushilal Sharma Government (Autonomous) Ayurveda College and Institute, Bhopal, for their dedicated involvement in academic discussions, literature review, and technical assistance during the preparation of this manuscript.

REFERENCES

1. International Diabetes Federation. IDF Diabetes Atlas. 10th ed. Brussels: IDF, 2021.
2. DeFronzo RA. Pathogenesis of type 2 diabetes mellitus. Med Clin North Am., 2004; 88(4): 787–835.
3. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care, 2023; 46(1): S1–S291.
4. Agnivesha. Charaka Samhita, Nidana Sthana 4. Varanasi: Chaukhambha, 2015.
5. Sushruta. Sushruta Samhita, Nidana Sthana 6. Varanasi: Chaukhambha, 2016.
6. Agnivesha. Charaka Samhita, Chikitsa Sthana 6. Varanasi: Chaukhambha, 2015.
7. Agnivesha. Charaka Samhita, Sutra Sthana 17. Varanasi: Chaukhambha, 2015.
8. Sharma RK, Dash B. Charaka Samhita (English translation). Varanasi: Chowkhamba, 2014.
9. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance. Nature, 2006; 444: 840–846.
10. Hotamisligil GS. Inflammation and metabolic disorders. Nature, 2006; 444: 860–867.
11. Eckel RH et al. The metabolic syndrome. Lancet, 2005; 365: 1415–1428.
12. Vagbhata. Ashtanga Hridaya, Kalpa Sthana 2. Varanasi: Chaukhambha, 2014.
13. Agnivesha. Charaka Samhita, Sutra Sthana 16. Varanasi: Chaukhambha, 2015.
14. Saltiel AR, Kahn CR. Insulin signalling and regulation. Nature, 2001; 414: 799–806.
15. Shoelson SE et al. Inflammation and insulin resistance. J Clin Invest, 2006; 116: 1793–1801.
16. Donath MY, Shoelson SE. Type 2 diabetes as inflammatory disease. Nat Rev Immunol, 2011; 11: 98–107.

17. Pradhan AD et al. Inflammatory biomarkers and diabetes risk. JAMA, 2001; 286: 327–334.
18. Ehses JA et al. IL-1β role in type 2 diabetes. Nat Med., 2009; 15: 269–276.
19. Cani PD et al. Metabolic endotoxemia. Diabetes, 2007; 56: 1761–1772.
20. Brownlee M. The pathobiology of diabetic complications. Nature, 2001; 414: 813–820.
21. Evans JL et al. Oxidative stress and diabetes. Endocr Rev., 2002; 23: 599–622.
22. Kirtikar KR, Basu BD. Indian Medicinal Plants. 2nd ed. Dehradun: International Book, 1999.
23. Pandey KB, Rizvi SI. Plant polyphenols as antioxidants. Oxid Med Cell Longev, 2009; 2: 270–278.
24. Turnbaugh PJ et al. Gut microbiome and obesity. Nature, 2006; 444: 1027–1031.
25. Cani PD, Delzenne NM. Role of LPS in metabolic diseases. Gut., 2009; 58: 1091–1103.
26. Gurung M et al. Gut microbiota in T2DM. Endocr Rev., 2020; 41: bnz002.
27. Lefebvre P et al. Role of bile acids in metabolism. Physiol Rev., 2009; 89: 147–191.
28. Thomas C et al. TGR5-mediated GLP-1 secretion. Cell Metab, 2009; 10: 167–177.
29. Chrousos GP. Stress and metabolic syndrome. Ann N Y Acad Sci., 2006; 1083: 1–14.
30. Peterson CT et al. Panchakarma and metabolic biomarkers. J Altern Complement Med., 2018; 24: 1–9.